GlassScriptPhysician profile
Shannon Wuestenberg
NPI 1356109490
$1,339.56
in general payments reported to CMS, 2019-2025
18 companies · $834 in 2025
The $834 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $506 · 2025: $834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,240 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,239.57 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $212.01 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $200.44 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $164.30 | 2024-2025 | Veozah |
| Sumitomo Pharma America, INC. | $103.26 | 2024-2025 | Gemtesa |
| Abbvie INC. | $88.07 | 2024-2025 | |
| Exact Sciences Corporation | $80.79 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $66.61 | 2024-2025 | Xarelto, Spravato |
| Pfizer INC. | $54.96 | 2025 | |
| Sanofi-Aventis U.S. LLC | $54.65 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $54.21 | 2024 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.43 | 2025 | Xifaxan |
| Dexcom, INC. | $46.47 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $38.88 | 2025 | Prolia, Evenity, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.57 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $30.24 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $25.11 | 2025 | Neffy |
| Genzyme Corporation | $21.04 | 2025 | |
| Inspire Medical Systems, INC. | $14.52 | 2024 | Inspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shannon Wuestenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.